Toripalimab Injection
Toripalimab Injection is an intervention with 22 clinical trials. Currently 10 active trials ongoing. Historical success rate of 50.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
12
Early Stage
4
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
1 of 2 finished
50.0%
1 ended early
10
trials recruiting
22
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Clinical Trials (22)
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors
PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma
PD-1 Antibody for Reactive EBV After BMT
PD-1 Antibody Improve Mixed Chimerism
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy
Drug Details
- Intervention Type
- COMBINATION PRODUCT
- Total Trials
- 22